EYLEA Drug Market Expected to Reach US$ 16.71 billion by 2032

The EYLEA drug market, projected to reach a valuation of US$ 10.14 billion in 2025, is set for consistent growth. Estimates indicate the market will grow to US$ 16.71 billion by 2032, registering a CAGR of 7.4% during the forecast period. Key factors driving this growth include the rising prevalence of retinal diseases such as age-related macular degeneration (AMD) and diabetic macular edema (DME), along with increasing geriatric population globally. Additionally, advancements in drug delivery systems and ongoing clinical trials exploring broader indications for EYLEA are anticipated to further boost demand. Strong support from regulatory agencies and the expansion of ophthalmic care services across developing regions are also contributing to the market’s positive outlook.

The full report is now available for purchase: https://www.coherentmi.com/industry-reports/global-eylea-drug-market

The global EYLEA drug market is experiencing robust growth, driven by the increasing incidence of conditions such as Wet Age-Related Macular Degeneration (Wet AMD), Diabetic Retinopathy (DR), and Diabetic Macular Edema (DME). These are significantly expanding the pool of patients in need of advanced ophthalmic therapies like EYLEA. These factors are boosting demand for long-acting, effective treatment options that can slow disease progression and preserve vision.

For instance, a study published by the National Library of Medicine in June 2023 highlighted that approximately 9.6 million individuals with diabetes were diagnosed with diabetic retinopathy, accounting for 26.4% of the diabetic population. Notably, 1.84 million of these cases were classified as vision-threatening diabetic retinopathy, underscoring the urgency for effective treatment modalities.

In addition, improved healthcare infrastructure and increasing investments in ophthalmology across developing regions such as Asia Pacific and Latin America are accelerating the market growth. Government initiatives and private sector engagement are enhancing screening capabilities, treatment accessibility, and public awareness—leading to earlier diagnosis and timely intervention.

There is a growing preference for retinal treatments that offer extended durability and reduced injection frequency. Innovations such as EYLEA HD (higher-dose aflibercept) and biosimilars, as well as emerging therapies like port delivery systems and gene therapy candidates, are addressing patient burden and compliance issues by minimizing the need for frequent intravitreal injections.

In May 2025, the European Medicines Agency (EMA) recommended extending the dosing interval for EYLEA 8 mg (aflibercept) to every six months for treating wet age-related macular degeneration (nAMD) and diabetic macular edema (DME). This is an improvement over the previous maximum interval of five months and offers a potential competitive advantage over rival treatments.

Artificial intelligence (AI) and optical coherence tomography (OCT) are transforming retinal diagnostics by enabling faster, more accurate detection of early-stage disease. AI-powered screening tools are particularly valuable in primary care and teleophthalmology settings, allowing for early identification of retinal pathologies and timely referrals to specialists.

In May 2024, the U.S. Food and Drug Administration (FDA) approved a portable retinal screening device co-developed by Optomed Oyj and AEYE Health. This device utilizes AI to analyze retinal images captured by a handheld fundus camera, facilitating the rapid detection of eye conditions, particularly diabetic retinopathy. The AI system enables autonomous screening in under a minute, enhancing accessibility to early diagnosis, especially in underserved areas.

Increased awareness among pediatric ophthalmologists and neonatal care providers about the long-term consequences of untreated retinopathy of prematurity (ROP)—a leading cause of childhood blindness in preterm infants—is accelerating early diagnosis and intervention. Healthcare systems and regulatory bodies are supporting the adoption of pharmacologic treatments to reduce reliance on invasive procedures like laser photocoagulation.

In February 2023, the U.S. Food and Drug Administration (FDA) approved EYLEA (aflibercept) as the first pharmacologic treatment for ROP in preterm infants. This approval was based on the FIREFLEYE and BUTTERFLEYE Phase 3 clinical trials, which showed that approximately 80% of EYLEA-treated infants experienced resolution of active ROP and avoided structural complications at 52 weeks of age.

As healthcare systems worldwide transition toward value-based care, pharmaceutical therapies that demonstrate strong real-world efficacy, lower complication rates, and reduced hospital visits are gaining priority among payers and providers. EYLEA HD (aflibercept 8 mg), with its extended dosing intervals and strong clinical outcomes, is well-positioned to align with these evolving reimbursement standards by reducing healthcare utilization and improving patient adherence.

In 2025, Regeneron presented real-world outcomes from nearly 40,000 patients treated with EYLEA HD, highlighting that clinical benefits observed in controlled trials—such as improved vision stability and reduced treatment frequency—were replicated in everyday practice. These findings validate the drug's cost-effectiveness and therapeutic value in routine care settings.

Moreover, the ability of EYLEA HD to sustain treatment effects with fewer injections supports the economic goals of value-based healthcare models. By reducing the frequency of clinic visits and improving long-term visual outcomes, it minimizes the burden on both healthcare providers and patients. These attributes are critical in negotiations for performance-based pricing and formulary inclusion, particularly in high-expenditure markets like the U.S. and Europe.

“The global EYLEA drug market is progressing with strong momentum, propelled by the increasing incidence of retinal diseases such as wet age-related macular degeneration (Wet AMD) and diabetic macular edema (DME),” says Mr. Ghanshyam Shrivastava, a Principal Consultant. “EYLEA’s clinical reliability, coupled with recent regulatory milestones—including its approval for retinopathy of prematurity (ROP)—is reinforcing its therapeutic relevance. The launch of EYLEA HD with extended dosing intervals is particularly impactful, addressing a critical patient and provider need for reduced treatment frequency in chronic retinal conditions.”

“Health systems are steadily transitioning toward value-based reimbursement models, where treatment outcomes and real-world effectiveness carry greater weight,” Mr. Ghanshyam Shrivastava adds. “In this context, Regeneron’s 2025 presentation of real-world data from nearly 40,000 patients offers compelling evidence supporting EYLEA HD’s role in lowering healthcare utilization and improving adherence. These findings enhance EYLEA’s positioning in formulary negotiations, particularly in the U.S. and European markets, where payers are prioritizing cost-efficient, outcome-driven therapies.”

“Looking forward, emerging economies in Asia Pacific and Latin America are poised to become key growth frontiers as ophthalmic infrastructure matures and access to advanced diagnostics improves,” he notes. “AI-powered retinal imaging tools and portable diagnostic devices are enabling earlier disease detection and broader screening coverage. Combined with strategic expansion into new indications and real-world performance validation, EYLEA is well-placed to remain a cornerstone in the global retinal therapy market, with sustained demand driven by innovation, access, and aging populations.”